Weight-Loss Drug Demand Drives Rapid Sales Growth for Healthcare Tech Firm
New York, Friday, 13 November 2026.
DataMEDS AI achieved 50% revenue growth to reach $2.7 million in the third quarter of 2026, fueled by weight-loss drug prescriptions and expanding diagnostic services.
Record-Breaking Growth in Third-Quarter 2026
DataMEDS AI (NASDAQ: MEDS) reported a 50% sequential revenue surge to $2.7 million in Q3 2026, up from $1.8 million in Q2 2026, as disclosed in its November 13, 2026 earnings release [1]. The company attributed this growth to expanded prescription dispensing through its Corexa Pharmacy subsidiary, particularly FDA-approved GLP-1 weight-loss medications and associated treatments [1]. Corexa Pharmacy’s distribution network expanded through partnerships with organizations like NFL Alumni Health, which provided a unique patient acquisition channel for GLP-1 medications and the medical food Forzet™, designed to manage muscle loss associated with weight-loss therapies [1]. This performance marked a dramatic turnaround from Q3 2025, when the company reported a net operating loss of $34.318 million [1].
Profitability Achieved Amid Strategic Expansion
The company achieved a net profit per share of $2.72 in Q3 2026, calculated on 3.961 million weighted average shares outstanding [1]. This compared to a net loss of $23.07 per share on 1.488 million shares in the prior-year quarter [1]. Gerald Commissiong, Interim Co-CEO, emphasized that the growth was underpinned by multiple revenue streams, stating, ‘Corexa Pharmacy drove a 50% sequential increase in revenue this quarter with continued growth expected for the fourth quarter based upon the steps we have taken to add additional revenue streams of medical foods and diagnostic lab tests related to patients to whom we dispense prescriptions’ [1]. The company also reported a net operating profit of $10.535 million for the quarter ended September 30, 2026 [1].
Diagnostics and AI Integration Strengthen Long-Term Outlook
DataMEDS AI further diversified its business model in Q3 2026 through the acquisition of Helomics Corporation, a CLIA-certified cancer diagnostics laboratory based in Pittsburgh, Pennsylvania [1]. The acquisition added proprietary revenue streams through the ChemoFx® Assay, which secured Medicaid coverage via Humana, positioning the company to capitalize on the growing oncology diagnostics market [1]. Additionally, the company secured an exclusive license to the REBOOT GLP-1 patient management platform and its associated intellectual property, enabling AI-assisted tools to enhance patient engagement and long-term value retention [1]. On October 19, 2026, DataMEDS AI regained full compliance with Nasdaq’s minimum bid price and stockholders’ equity requirements, following a reverse stock split in May 2026 and subsequent equity conversions [5].
Market Position and Future Growth Drivers
DataMEDS AI operates in a rapidly expanding market, with U.S. retail prescription drug spending reaching $405.9 billion in 2022 and expected to grow further as the weight-loss drug market continues to surge [7]. The company’s strategic initiatives include the launch of the ‘Health Lives Here’ mobile app, developed in partnership with NFL Alumni Health, which serves as a customer acquisition tool for Corexa Pharmacy’s GLP-1 medications [1]. An MOU with a Florida-based HMO to deploy the app to over 25,000 members is expected to finalize in Q4 2026, providing an institutional revenue opportunity [1]. Commissiong highlighted the company’s diversified growth strategy, noting, ‘Health Lives Here, backed by NFL Alumni Health, brings patients to Corexa Pharmacy. The REBOOT license gives us patented, AI-assisted tools to keep GLP-1 patients engaged, proprietary Tollo Health medical foods for muscle loss associated with weight loss therapies gives them unique tools to mitigate the drugs’ side effects and Helomics adds diagnostic testing revenue streams’ [1].
Financial Health and Regulatory Compliance
As of September 30, 2026, DataMEDS AI reported total assets of $38.73 million, cash and cash equivalents of $476,598, and total liabilities of $38.56 million [1]. The company’s ability to regain Nasdaq compliance in October 2026, following the conversion of approximately $1.5 million in vendor payables from July to October 2026, underscored its improved financial discipline [5]. DataMEDS AI’s market capitalization stood at $92.38 million as of November 12, 2026, with its shares trading at $1.18 per share on the Nasdaq Capital Market [6]. The company’s financial resilience was further evidenced by its acquisition of Helomics Corporation for 636,328 common shares and a $1.36 million convertible promissory note, finalized on September 11, 2026 [5].